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z Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USAMuch excitement has been generated with the advent of
magnetic resonance imaging (MRI) techniques to directly
visualize cartilage structure and molecular composition
in vivo. There is no question that development of non-
destructive imaging methods for evaluating the biochemical
state of cartilage has the potential to revolutionize the ap-
proaches to understanding degeneration and for evaluating
therapeutic efﬁcacy. And, given the prevalence of disability
resulting from cartilage degeneration, there is a societal and
medical imperative to understand and better address de-
generation. After more than a decade’s worth of exploring
the capabilities of various MRI parameters and the recent
application of several of those parameters in clinical OA tri-
als, perhaps it is time to examine whether molecular MRI is
fulﬁlling its promise, and what might be done as the ﬁeld
moves forward. As a number of important tissue character-
istics need to be interrogated, several MRI metrics will most
likely be needed for a full evaluation of cartilage. Here we
discuss in particular the three parameters which have
been implemented for observing different molecular aspects
of cartilage in clinical trials of OA.
Perhaps the most widely implemented MR parameter ap-
plied to cartilage molecular imaging is T2. Quantitative T2
has been the subject of numerous studies since 1989
when the variation of T2 across cartilage was demon-
strated1. T2 is an MR relaxation time reﬂecting interactions
between water molecules and between water and surround-
ing macromolecules, with increasing interaction resulting in
a decreased T2. Not surprisingly, T2 is affected by many
physiologic and pathophysiologic processes that relate to
the state of cartilage.
There has been a prevailing general impression from the
literature that T2 is expected to increase with degeneration,
as both the disruption of cartilage architecture and increa-
sed hydration that are normally associated with cartilage
degeneration generally increase T2. Indeed, a number of re-
ports demonstrate increasedT2with cartilagedegeneration2e4
and in individuals with OA relative to healthy volunteers5,6.
Conversely, what have not been recognized as much
are data demonstrating unchanged or decreased T2 with
in vitro degeneration7e10 and in clinical T2 images11,12. It
has been hypothesized that collagenase induced collagen
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water and the collagen molecule, decreasing T29.
In osteoarthritis, many factors involved in cartilage
degeneration are likely to be present, with two important
implications: ﬁrst, the competing factors may offset each
other leading to much reduced sensitivity to disease. This
may be the reason for the relatively disappointing results
in prior studies of T2 of little or inconsistent changes in T2
in various stages of disease2,4,6,8,9,13,14.
Second, a lack of appreciation of the competing factors
may lead to misinterpretation of T2 data in a way that
may confound efforts to ﬁnd effective therapies. For exam-
ple, consider a trial of a therapeutic intervention (such as
disease modifying drugs) that inhibits the action (or produc-
tion) of collagenase. In this case the positive effect of the
intervention (less cleavage of molecules) might lead to an
increased T2 (fewer water interaction sites); yet at present
an increased T2 would likely be misinterpreted as increased
cartilage degeneration.
This is not an issue of the accuracy of the T2 measure-
ments themselves15 or of the spatial resolution over which
T2 is analyzed, as the inherent competing tissue effects
would be present even with perfect, regionalized T2 mea-
surements and analysis.
Thus, a large number of careful T2 studies have been
done to date. From the aggregate information obtained
thus far, it is important to acknowledge that it is not presently
possible to interpret a change in T2 as reﬂecting an improve-
ment or decline of the state of cartilage in clinical trials of OA,
where multiple biological and mechanical effects are pres-
ent, each of which may drive T2 in different directions.
This conclusion does not diminish the potential role of T2 in
more controlled situations, for example the investigation of col-
lagen architectural structure in intact cartilage16, with cartilage
development17, or mechanical effects on in vivo cartilage18.
In addition to T2, two other methods for molecular MRI of
cartilage degeneration have received much attention: T1rho
and delayed Gadolinium Enhanced MRI of Cartilage (dGEM-
RIC). T1rho (T1 in the rotating frame) is similar to T2 in that it
is affected by general interactions between water and macro-
molecules. T1rho was initially proposed to be relatively spe-
ciﬁc for glycosaminoglycan (GAG)19. In support of that
notion, several studies have illustrated changes in T1rho in
response to interventions that reduced tissue GAG8,20,21.
However, one must keep in mind that T1rho is also
sensitive to numerous cartilage factors, particularly hydra-
tion, GAG, and collagen9,22. Furthermore, like T2, factors7
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tial and competing effects on T1rho; the competing effects
may explain the results where T1rho was not affected in
some cases of cartilage degeneration9,19.
Thus, although shown to have a larger dynamic range
than T24, the overall literature results do not support a gen-
eralized interpretation of T1rho. T1rho is sensitive to many
competing factors, and demands the same caution in inter-
pretation of improvement or degeneration of cartilage as
does T2.
dGEMRIC is a method designed to measure ﬁxed charge
density in cartilage, adapting established approaches pio-
neered by Maroudas et al.23e25. The technique is based
on the premise that mobile ions will distribute in cartilage
in relation to the concentration of the charged GAG mole-
cules. In this method the mobile ion is the MRI contrast
agent Gd(DTPA)2 (Magnevist, Berlex, NJ). In part because
of the biophysical basis for dGEMRIC, the long-known fact
that cartilage matrix charge is dominated by GAG, and the
intrinsic ability to measure Gd(DTPA)2 concentration by
MRI, theoretically dGEMRIC should be straightforward to
interpret, and speciﬁc for GAG.
Yet, questions remain regarding the direct correspon-
dence of dGEMRIC to GAG concentration in vivo. These
include conditions which might impact the dosing of
Gd(DTPA)2 to yield a given plasma Gd(DTPA)2concen-
tration (BMI, or percentage of adipose vs lean tissue
mass)26, transport of Gd(DTPA)2 into cartilage (synovitis,
bone sclerosis)27 and assumptions made in converting the
MRI measurement of T1 to Gd(DTPA)2 concentration (var-
iations in T1 without Gd(DTPA)2 and contrast agent
Gd(DTPA)2 ‘‘relaxivity’’)28. These issues need further
work for clariﬁcation under different clinical scenarios of OA.
Because of these questions, reports to date describe
in vivo ﬁndings in terms of the ‘‘dGEMRIC Index’’. Several
reports have demonstrated ﬁndings relating the dGEMRIC
Index to pathologic processes and therapeutic
interventions26,29e36.
While these individual studies show promise, implemen-
tation of dGEMRIC has been relatively limited. Although
the method does not require any specialized equipment,
the technique can be inconvenient (e.g., it requires approx-
imately a 2 h delay between injection of the contrast agent
and imaging), and the pulse sequences are not routinely
available. The implementation is dependent upon different
manufacturer’s MRI platforms, and sharing of the software
pulse sequences amongst investigators is difﬁcult.
Indeed, this is a general issue: investigations of T2 and
T1rho are also hampered by difﬁculties of appropriately
installing MRI pulse sequences for the measurements.
Enabling a more open collaboration between MRI groups
is essential for obtaining in vivo data and for the ﬁeld to
progress more rapidly.
Several other parameters for interrogating cartilage
molecular composition, structure, and architecture have
been evaluated, including sodium MRI37,38, diffusion and
diffusion tensor imaging39e42, and magnetization trans-
fer43e46. In general they have been limited by difﬁculties
in in vivo implementation, poor spatial resolution, and/or
limited sensitivity to degeneration, and are not currently
being used in clinical trials.
Where are we?
In summary, results to date have yielded substantial infor-
mation on MRI parameters in the evaluation of OA. Yet,
important challenges remain in studying, implementing,and interpreting MR studies of cartilage molecular structure
and composition. Due to the competing effects of different
aspects of cartilage degeneration on T2, we believe that
the interpretation of T2 as reﬂecting an improvement or
decline of the disease state in clinical trials of OA is not cur-
rently possible. As a particular concern, the competing
effects might lead to misinterpretation of progression or
regression of natural disease and studies involving disease
modifying drugs, where aspects of collagen molecular
structure might be impacted and offset (or dominate) the
effects of loss of architectural structure and increased
hydration. T1rho, while demonstrating improved dynamic
range as compared with T2, has the same inherent difﬁculty
of competing multifactorial components with their associ-
ated potential misinterpretation that needs to be acknowl-
edged and addressed. dGEMRIC has a clear theoretical
basis for speciﬁcity to GAG, and its use in limited clinical
studies has offered interesting insights, but issues related
to dosing and transport of contrast agent, and conversion
of T1 to Gd(DTPA)2 concentration need to be addressed,
and its utility is limited by difﬁculties in widespread imple-
mentation. Other MRI parameters which have been investi-
gated have not demonstrated the required sensitivity or
speciﬁcity for clinical trials of OA.
Have we delivered on the promise of MR for evaluating
cartilage in OA? A great deal more is known now than 15
years ago when this ﬁeld essentially began. And the need
for imaging markers of OA is as great as ever. However,
signiﬁcant problems remain in implementation and inter-
pretation of the currently proposed parameters if they
are to provide insight into OA progression and treatment,
and it is not clear that these problems are surmountable.
As a community we need to encourage critical discussion
about the objectives and adequacy of the many proposed
imaging approaches, and investigate the possibility of
new approaches. This will require input from varied
communities of biologists, clinicians, physicists, chemists,
and instrument manufacturers. With such interactions, we
can further the potential for imaging approaches to aid in
the development of therapeutic and preventative strate-
gies to alleviate the disability associated with cartilage
degeneration.
References
1. Lehner KB, Rechl HP, Gmeinwieser JK, Heuck AF,
Lukas HP, Kohl HP. Structure, function, and degener-
ation of bovine hyaline cartilage: assessment with MR
imaging in vitro. Radiology 1989;170:495e9.
2. David-Vaudey E, Ghosh S, Ries M, Majumdar S. T2 re-
laxation time measurements in osteoarthritis. Magn
Reson Imaging 2004;22:673e82.
3. Watrin-Pinzano A, Ruaud JP, Olivier P, Grossin L,
Gonord P, Blum A, et al. Effect of proteoglycan deple-
tion on T2 mapping in rat patellar cartilage. Radiology
2005;234:162e70.
4. Regatte RR, Akella SV, Lonner JH, Kneeland JB,
Reddy R. T1rho relaxation mapping in human osteoar-
thritis (OA) cartilage: comparison of T1rho with T2.
J Magn Reson Imaging 2006;23:547e53.
5. Mosher TJ, Dardzinski BJ, Smith MB. Human articular
cartilage: inﬂuence of aging and early symptomatic de-
generation on the spatial variation of T2dpreliminary
ﬁndings at 3 T. Radiology 2000;214:259e66.
6. Dunn TC, Lu Y, Jin H, Ries MD, Majumdar S. T2 relax-
ation time of cartilage at MR imaging: comparison with
1089Osteoarthritis and Cartilage Vol. 14, No. 11severity of knee osteoarthritis. Radiology 2004;232:
592e8.
7. Henkelman RM, Stanisz GJ, Menezes N, Burstein D.
Can MTR be used to assess cartilage in the presence
of Gd-DTPA2? Magn Reson Med 2002;48:
1081e4.
8. Regatte RR, Akella SV, Borthakur A, Kneeland JB,
Reddy R. Proteoglycan depletion-induced changes in
transverse relaxation maps of cartilage: comparison
of T2 and T1rho. Acad Radiol 2002;9:1388e94.
9. Menezes NM, Gray ML, Hartke JR, Burstein D. T2 and
T1rho MRI in articular cartilage systems. Magn Reson
Med 2004;51:503e9.
10. Mendlik T, Wagner S, Schulz S, Milz S, Rauch E,
Reiser M, et al. How Does Cartilage T2 Change
After Selective Enzymatic Degradation? Miami Beach,
Florida: International Society for Magnetic Resonance
in Medicine.
11. Dray N, Williams A, Prasad PV, Sharma L, Burstein D.
T2 in an OA Population: Metrics for Reporting Data?
Miami Beach, Florida: International Society for Mag-
netic Resonance in Medicine p. 1995.
12. Burstein D. MRI for development of disease-modifying
osteoarthritis drugs. NMR in Biomedicine 2006;19:
1e12.
13. NieminenM, Jurvelin J, Kiviranta I, To¨yra¨s J, Kiviranta P,
Lammentausta E. Relationship of T2 and dGEMRIC
with histologically veriﬁed degeneration of human carti-
lage at 1.5 T. Seattle, 2006 May, p. 55.
14. Koff M, Amrami K, Kaufman K. T2 Values of Patellar
Cartilage in Subjects with Osteoarthritis. Seattle: Inter-
national Society for Magnetic Resonance in Medicine
p. 56.
15. Maier CF, Tan SG, Hariharan H, Potter HG. T2 quanti-
tation of articular cartilage at 1.5 T. J Magn Reson Im-
aging 2003;17:358e64.
16. Xia Y, Moody JB, Burton-Wurster N, Lust G. Quantita-
tive in situ correlation between microscopic MRI and
polarized light microscopy studies of articular carti-
lage. Osteoarthritis Cartilage 2001;9:393e406.
17. Xia Y, Moody JB, Alhadlaq H, Hu J. Imaging the phys-
ical and morphological properties of a multi-zone
young articular cartilage at microscopic resolution.
J Magn Reson Imaging 2003;17:365e74.
18. Mosher TJ, Smith HE, Collins C, Liu Y, Hancy J,
Dardzinski BJ, et al. Change in knee cartilage T2 at
MR imaging after running: a feasibility study. Radiol-
ogy 2005;234:245e9.
19. Duvvuri U, Reddy R, Patel SD, Kaufman JH,
Kneeland JB, Leigh JS. T1rho-relaxation in articular
cartilage: effects of enzymatic degradation. Magn Re-
son Med 1997;38:863e7.
20. Akella SV, Regatte RR, Gougoutas AJ, Borthakur A,
Shapiro EM, Kneeland JB, et al. Proteoglycan-induced
changes in T1rho-relaxation of articular cartilage at 4T.
Magn Reson Med 2001;46:419e23.
21. Wheaton AJ, Dodge GR, Borthakur A, Kneeland JB,
Schumacher HR, Reddy R. Detection of changes
in articular cartilage proteoglycan by T(1rho) mag-
netic resonance imaging. J Orthop Res 2005;23:
102e8.
22. Gibbons B, Luci J, Gore J. Complications in the quan-
tiﬁcation of GAG in cartilage with T1rho imaging.
Seattle, 2006 May, p. 1247.
23. Maroudas A. Physicochemical properties of cartilage in
the light of ion exchange theory. Biophys J 1968;8:
575e95.24. Maroudas A, Muir H, Wingham J. The correlation of
ﬁxed negative charge with glycosaminoglycan content
of human articular cartilage. Biochim Biophys Acta
1969;177:492e500.
25. Maroudas A, Thomas H. A simple physicochemical mi-
cromethod for determining ﬁxed anionic groups in con-
nective tissue. Biochim Biophys Acta 1970;215:214e6.
26. Tiderius C, Hori M, Williams A, Sharma L, Prasad PV,
FinnellM, et al. dGEMRICas a function of BMI. Osteoar-
thritis Cartilage 2006;14(11):1091e7.
27. Burstein D, Velyvis J, Scott KT, Stock KW, Kim YJ,
Jaramillo D, et al. Protocol issues for delayed
Gd(DTPA)(2)-enhanced MRI (dGEMRIC) for clinical
evaluation of articular cartilage. Magn Reson Med
2001;45:36e41.
28. Gillis A, Gray M, Burstein D. Relaxivity and diffusion of
gadolinium agents in cartilage. Magn Reson Med
2002;48:1068e71.
29. Tiderius CJ, Olsson LE, Leander P, Ekberg O,
Dahlberg L. Delayed gadolinium-enhanced MRI of car-
tilage (dGEMRIC) in early knee osteoarthritis. Magn
Reson Med 2003;49:488e92.
30. Kim YJ, Jaramillo D, Millis MB, Gray ML, Burstein D.
Assessment of early osteoarthritis in hip dysplasia
with delayed gadolinium-enhanced magnetic reso-
nance imaging of cartilage. J Bone Joint Surg Am
2003;85-A:1987e92.
31. Williams A, Sharma L, McKenzie CA, Prasad PV,
Burstein D. Delayed gadolinium-enhanced magnetic
resonance imaging of cartilage in knee osteoarthritis:
ﬁndings at different radiographic stages of disease
and relationship to malalignment. Arthritis Rheum
2005;52:3528e35.
32. Young AA, Stanwell P, Williams A, Rohrsheim JA,
Parker DA, Giuffre B, et al. Glycosaminoglycan
content of knee cartilage following posterior cruciate
ligament rupture demonstrated by delayed gadoli-
nium-enhanced magnetic resonance imaging of carti-
lage (dGEMRIC). A case report. J Bone Joint Surg
Am 2005;87:2763e7.
33. Tiderius CJ, Olsson LE, Nyquist F, Dahlberg L. Carti-
lage glycosaminoglycan loss in the acute phase after
an anterior cruciate ligament injury: delayed gadoli-
nium-enhanced magnetic resonance imaging of carti-
lage and synovial ﬂuid analysis. Arthritis Rheum
2005;52:120e7.
34. Nojiri T, Watanabe N, Namura T, Narita W, Ikoma K,
Suginoshita T, et al. Utility of delayed gadolinium-en-
hanced MRI (dGEMRIC) for qualitative evaluation of
articular cartilage of patellofemoral joint. Knee Surg
Sports Traumatol Arthrosc 2006:1e6.
35. Cunningham T, Jessel R, Zurakowski D, Millis MB,
Kim YJ. Delayed gadolinium-enhanced magnetic
resonance imaging of cartilage to predict early failure
of Bernese periacetabular osteotomy for hip dysplasia.
J Bone Joint Surg Am 2006;88:1540e8.
36. Wilson DC, Maedler B, Garbuz DS, Duncan CP,
Eckstein F, Wilson DR. Localized Cartilage Assess-
ment with Three-dimentional dGEMRIC and Quantita-
tive MRI in Patients with Femoroacetabular
Impingement. Miami Beach, Florida: International
Society for Magnetic Resonance in Medicine.
37. Lesperance LM, Gray ML, Burstein D. Determination
of ﬁxed charge density in cartilage using nuclear
magnetic resonance. J Orthop Res 1992;10:1e13.
38. Wheaton AJ, Borthakur A, Dodge GR, Kneeland JB,
Schumacher HR, Reddy R. Sodium magnetic
1090 D. Burstein and M. L. Gray: MRI for molecular imaging of cartilageresonance imaging of proteoglycan depletion in an
in vivo model of osteoarthritis. Acad Radiol 2004;11:
21e8.
39. Burstein D, Gray ML, Hartman AL, Gipe R, Foy BD-
Diffusion of small solutes in cartilage as measured
by nuclear magnetic resonance (NMR) spectroscopy
and imaging. J Orthop Res 1993;11:465e78.
40. Mlynarik V, Sulzbacher I, Bittsansky M, Fuiko R,
Trattnig S. Investigation of apparent diffusion con-
stant as an indicator of early degenerative disease
in articular cartilage. J Magn Reson Imaging 2003;
17:440e4.
41. Filidoro L, Dietrich O, Weber J, Rauch E, Oerther T,
Wick M, et al. High-resolution diffusion tensor imaging
of human patellar cartilage: feasibility and preliminary
ﬁndings. Magn Reson Med 2005;53:993e8.42. Deng X, Farley M, Gray M, Burstein D. Diffusion tensor
imaging in cartilage. Miami, Florida, 2005.
43. Wolff SD, Chesnick S, Frank JA, Lim KO, Balaban RS.
Magnetization transfer contrast: MR imaging of the
knee. Radiology 1991;179:623e8.
44. Gray ML, Burstein D, Lesperance LM, Gehrke L. Mag-
netization transfer in cartilage and its constituent mac-
romolecules. Magn Reson Med 1995;34:319e25.
45. Seo GS, Aoki J, Moriya H, Karakida O, Sone S,
Hidaka H, et al. Hyaline cartilage: in vivo and in vitro
assessment with magnetization transfer imaging.
Radiology 1996;201:525e30.
46. Wachsmuth L, Juretschke HP, Raiss RX. Can magne-
tization transfer magnetic resonance imaging follow
proteoglycan depletion in articular cartilage? MAGMA
1997;5:71e8.
